Tosi Davide, Mendogni Paolo, Carrinola Rosaria, Palleschi Alessandro, Rosso Lorenzo, Bonaparte Eleonora, Cribiù Fulvia Milena, Ferrero Stefano, Bonitta Gianluca, Nosotti Mario
Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
J Thorac Dis. 2019 Mar;11(3):724-731. doi: 10.21037/jtd.2019.02.58.
Many studies on fine-needle aspiration biopsy (FNAB) for undetermined pulmonary nodules reported that diagnostic accuracy tended to decline, whereas complication prevalence raised as the size of nodule decreased. Reconsideration on the effectiveness of FNAB would be appropriate considering the dramatic increase in the identification of small nodules with screening programs and new demands of target therapies. The aim of this study was to verify the efficacy of FNAB in pulmonary nodules smaller than 15 mm.
A retrospective, cohort study was conducted on patients with undetermined solitary pulmonary nodules (SPNs) who underwent computer tomography (CT) guided FNAB at our Institution from January 2012 to December 2014. Patients with SPNs with diameter up to 15 mm were considered; inclusion criteria comprised ASA 3, FEV1 <70% of predicted, cardiac comorbidity or previous chest surgery. FNAB diagnostic performance and clinical efficacy were calculated.
Out of 225 patients referred for FNAB, 68 covered inclusion criteria. Forty-nine out of 68 smears (72%) were adequate for diagnosis. Specificity was 100% (95% CI: 77-100%), sensitivity was 100% (95% CI: 90-100%). Positive and negative predictive values were 1.0 (95% CI: 0.9-1.0) and 1.0 (95% CI: 0.77-1.0) respectively. A post-biopsy pneumothorax was detected in 27 cases (39%); the pneumothorax rate was significantly affected by the number of passages (P=0.01).
The satisfactory results of our study lead to reconsidering FNAB in patients with pulmonary nodules below 15 mm in diameter, especially in order to avoid unnecessary surgery.
许多关于细针穿刺活检(FNAB)用于未明确的肺结节的研究报告称,随着结节尺寸减小,诊断准确性趋于下降,而并发症发生率上升。鉴于筛查项目中发现的小结节数量急剧增加以及靶向治疗的新需求,重新考虑FNAB的有效性是恰当的。本研究的目的是验证FNAB在直径小于15mm的肺结节中的疗效。
对2012年1月至2014年12月在本机构接受计算机断层扫描(CT)引导下FNAB的未明确的孤立性肺结节(SPN)患者进行了一项回顾性队列研究。纳入直径达15mm的SPN患者;纳入标准包括美国麻醉医师协会(ASA)分级为3级、第一秒用力呼气容积(FEV1)<预测值的70%、心脏合并症或既往胸部手术史。计算FNAB的诊断性能和临床疗效。
在225例接受FNAB的患者中,68例符合纳入标准。68份涂片中有49份(72%)足以用于诊断。特异性为100%(95%置信区间:77 - 100%),敏感性为100%(95%置信区间:90 - 100%)。阳性和阴性预测值分别为1.0(95%置信区间:0.9 - 1.0)和1.0(95%置信区间:0.77 - 1.0)。27例(39%)检测到活检后气胸;气胸发生率受穿刺次数的显著影响(P = 0.01)。
我们研究的满意结果促使重新考虑对直径小于15mm的肺结节患者进行FNAB,特别是为了避免不必要的手术。